{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T23:14:00Z","timestamp":1772147640632,"version":"3.50.1"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2021,6,9]],"date-time":"2021-06-09T00:00:00Z","timestamp":1623196800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,6,9]],"date-time":"2021-06-09T00:00:00Z","timestamp":1623196800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch Gynecol Obstet"],"published-print":{"date-parts":[[2021,11]]},"DOI":"10.1007\/s00404-021-06118-3","type":"journal-article","created":{"date-parts":[[2021,6,9]],"date-time":"2021-06-09T17:02:42Z","timestamp":1623258162000},"page":"1335-1343","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Association of preoperative serum HE4 levels on the survival of patients with endometrial cancer"],"prefix":"10.1007","volume":"304","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1894-4125","authenticated-orcid":false,"given":"Putsarat","family":"Insin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yani","family":"Yimyam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nisa","family":"Prueksaritanond","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,6,9]]},"reference":[{"key":"6118_CR1","doi-asserted-by":"publisher","DOI":"10.1177\/1010428318757103","author":"K Abbink","year":"2018","unstructured":"Abbink K, Zusterzeel PL, Geurts-Moespot AJ et al (2018) HE4 is superior to CA125 in the detection of recurrent disease in high-risk endometrial cancer patients. Tumour Biol. https:\/\/doi.org\/10.1177\/1010428318757103","journal-title":"Tumour Biol"},{"key":"6118_CR2","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.maturitas.2010.04.017","volume":"67","author":"P Aggarwal","year":"2010","unstructured":"Aggarwal P, Kehoe S (2010) Serum tumour markers in gynaecological cancers. Maturitas 67:46\u201353","journal-title":"Maturitas"},{"key":"6118_CR3","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1007\/s13277-012-0583-0","volume":"34","author":"R Angioli","year":"2013","unstructured":"Angioli R, Plotti F, Capriglione S et al (2013) The role of novel biomarker HE4 in endometrial cancer: a case control prospective study. Tumour Biol 34:571\u2013576","journal-title":"Tumour Biol"},{"key":"6118_CR4","first-page":"384","volume-title":"Fundamentals of biostatistics","author":"R Bernard","year":"2000","unstructured":"Bernard R (2000) Fundamentals of biostatistics, 5th edn. Thomson learning, Duxbery, pp 384\u2013385","edition":"5"},{"key":"6118_CR5","doi-asserted-by":"publisher","first-page":"1418","DOI":"10.1038\/bjc.2011.109","volume":"104","author":"E Bignotti","year":"2011","unstructured":"Bignotti E, Ragnoli M, Zanotti L et al (2011) Diagnostic and prognostic impact of serum HE4 detection in endometrial carcinoma patients. Br J cancer 104:1418\u20131425","journal-title":"Br J cancer"},{"key":"6118_CR6","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.ygyno.2013.10.036","volume":"132","author":"DJ Brennan","year":"2014","unstructured":"Brennan DJ, Hackethal A, Metcalf AM et al (2014) Serum HE4 as a prognostic marker in endometrial cancer\u2013a population-based study. Gynecol Oncol 132:159\u2013165","journal-title":"Gynecol Oncol"},{"key":"6118_CR7","doi-asserted-by":"publisher","first-page":"4151","DOI":"10.1007\/s13277-015-3049-3","volume":"36","author":"S Capriglione","year":"2015","unstructured":"Capriglione S, Plotti F, Miranda A et al (2015) Utility of tumor marker HE4 as prognostic factor in endometrial cancer: a single-center controlled study. Tumour Biol 36:4151\u20134156","journal-title":"Tumour Biol"},{"key":"6118_CR8","doi-asserted-by":"publisher","first-page":"S105","DOI":"10.1016\/S0020-7292(06)60031-3","volume":"95","author":"WT Creasman","year":"2006","unstructured":"Creasman WT, Odicino F, Maisonneuve P et al (2006) Carcinoma of the corpus uteri. FIGO 26th annual report on the results of treatment in gynecological cancer. Int J Gynaecol Obstet 95:S105-143","journal-title":"Int J Gynaecol Obstet"},{"key":"6118_CR9","doi-asserted-by":"publisher","first-page":"2162","DOI":"10.1158\/0008-5472.CAN-04-3924","volume":"65","author":"R Drapkin","year":"2005","unstructured":"Drapkin R, von Horsten HH, Lin Y et al (2005) Human epididymis protein 4 (HE4) is a secreted glycoprotein that is overexpressed by serous and endometrioid ovarian carcinomas. Cancer Res 65:2162\u20132169","journal-title":"Cancer Res"},{"key":"6118_CR10","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.12659\/MSM.890478","volume":"20","author":"F Falcone","year":"2014","unstructured":"Falcone F, Balbi G, Di Martino L et al (2014) Surgical management of early endometrial cancer: an update and proposal of a therapeutic algorithm. Med Sci Monit 20:1298\u20131313","journal-title":"Med Sci Monit"},{"key":"6118_CR11","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1016\/j.ygyno.2011.10.025","volume":"124","author":"E Kalogera","year":"2010","unstructured":"Kalogera E, Scholler N, Powless C et al (2010) Correlation of serum HE4 with tumor size and myometrial invasion in endometrial cancer. Gynecol Oncol 124:270\u2013275","journal-title":"Gynecol Oncol"},{"key":"6118_CR12","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1136\/ijgc-00009577-200505000-00001","volume":"15","author":"FM Kew","year":"2005","unstructured":"Kew FM, Roberts AP, Cruickshank DJ (2005) The role of routine follow-up after gynecological malignancy. Int J Gynecol Cancer 15:413\u2013419","journal-title":"Int J Gynecol Cancer"},{"key":"6118_CR13","doi-asserted-by":"publisher","first-page":"170","DOI":"10.6004\/jnccn.2018.0006","volume":"16","author":"WJ Koh","year":"2018","unstructured":"Koh WJ, Abu-Rustum NR, Bean S et al (2018) Uterine neoplasms, version 1.2018, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw 16:170\u2013199","journal-title":"J Natl Compr Canc Netw"},{"key":"6118_CR14","doi-asserted-by":"publisher","first-page":"2156","DOI":"10.4238\/2015.March.27.2","volume":"14","author":"YW Lv","year":"2015","unstructured":"Lv YW, Yang L, Zhang M et al (2015) Increased human epididymis protein 4 in benign gynecological diseases complicated with chronic renal insufficiency patients. Genet Mol Res 14:2156\u20132161","journal-title":"Genet Mol Res"},{"key":"6118_CR15","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/j.ygyno.2008.04.002","volume":"110","author":"RG Moore","year":"2008","unstructured":"Moore RG, Brown AK, Miller MC et al (2008) Utility of a novel serum tumor biomarker HE4 in patients with endometrioid adenocarcinoma of the uterus. Gynecol Oncol 110:196\u2013201","journal-title":"Gynecol Oncol"},{"key":"6118_CR16","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1016\/j.ygyno.2012.04.022","volume":"126","author":"I Mutz-Dehbalaie","year":"2012","unstructured":"Mutz-Dehbalaie I, Egle D, Fessler S et al (2012) HE4 is an independent prognostic marker in endometrial cancer patients. Gynecol Oncol 126:186\u2013191","journal-title":"Gynecol Oncol"},{"key":"6118_CR17","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.ijgo.2009.02.009","volume":"105","author":"S Pecorelli","year":"2009","unstructured":"Pecorelli S, Zigliani L, Odicino F (2009) Revised FIGO staging for carcinoma of the cervix. Int J Gynaecol Obstet 105:107\u2013108","journal-title":"Int J Gynaecol Obstet"},{"key":"6118_CR18","first-page":"585","volume":"50","author":"JL Powell","year":"2005","unstructured":"Powell JL, Hill KA, Shiro BC et al (2005) Preoperative serum CA-125 levels in treating endometrial cancer. J Reprod Med 50:585\u2013590","journal-title":"J Reprod Med"},{"issue":"3","key":"6118_CR19","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.7314\/APJCP.2016.17.3.1489","volume":"17","author":"N Prueksaritanond","year":"2016","unstructured":"Prueksaritanond N, Cheanpracha P, Yanaranop M (2016) Association of serum HE4 with primary tumor diameter and depth of myometrial invasion in endometrial cancer patients at Rajavithi Hospital. Asian Pac Cancer Prev 17(3):1489\u20131492","journal-title":"Asian Pac Cancer Prev"},{"key":"6118_CR20","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1016\/j.ajog.2011.03.008","volume":"204","author":"R Salani","year":"2011","unstructured":"Salani R, Backes FJ, Fung MF et al (2011) Posttreatment surveillance and diagnosis of recurrence in women with gynecologic malignancies: Society of Gynecologic Oncologists recommendations. Am J Obstet Gynecol 204:466\u2013478","journal-title":"Am J Obstet Gynecol"},{"key":"6118_CR21","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21387","volume":"67","author":"RL Siegel","year":"2017","unstructured":"Siegel RL, Miller KD, Jemal A (2017) Cancer statistics. CA Cancer J Clin 67:7\u201330","journal-title":"CA Cancer J Clin"},{"key":"6118_CR22","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1007\/s00428-017-2115-1","volume":"470","author":"A Stiekema","year":"2017","unstructured":"Stiekema A, Lok C, Korse CM et al (2017) Serum HE4 is correlated to prognostic factors and survival in patients with endometrial cancer. Virchows Arch 470:655\u2013664","journal-title":"Virchows Arch"},{"key":"6118_CR23","doi-asserted-by":"publisher","first-page":"125858","DOI":"10.1155\/2013\/125858","volume":"2013","author":"A Tessitore","year":"2013","unstructured":"Tessitore A, Gaggiano A, Cicciarelli G et al (2013) Serum biomarkers identification by mass spectrometry in high-mortality tumors. Int J Proteomics 2013:125858","journal-title":"Int J Proteomics"},{"key":"6118_CR24","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1097\/IGC.0000000000000306","volume":"25","author":"LJ van der Putten","year":"2015","unstructured":"van der Putten LJ, Geels YP, Ezendam NP et al (2015) Lymphovascular space invasion and the treatment of stage I endometrioid endometrial cancer. Int J Gynecol Cancer 25:75\u201380","journal-title":"Int J Gynecol Cancer"},{"key":"6118_CR25","doi-asserted-by":"publisher","first-page":"e65","DOI":"10.3802\/jgo.2016.27.e65","volume":"27","author":"S Wilailak","year":"2016","unstructured":"Wilailak S, Lertchaipattanakul N (2016) The epidemiologic status of gynecologic cancer in Thailand. J Gynecol Oncol 27:e65","journal-title":"J Gynecol Oncol"},{"key":"6118_CR26","doi-asserted-by":"publisher","first-page":"2189","DOI":"10.1515\/cclm-2011-0757","volume":"50","author":"L Zanotti","year":"2012","unstructured":"Zanotti L, Bignotti E, Calza S et al (2012) Human epididymis protein 4 as a serum marker for diagnosis of endometrial carcinoma and prediction of clinical outcome. Clin Chem Lab Med 50:2189\u20132198","journal-title":"Clin Chem Lab Med"}],"container-title":["Archives of Gynecology and Obstetrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00404-021-06118-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00404-021-06118-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00404-021-06118-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,5]],"date-time":"2021-10-05T03:43:47Z","timestamp":1633405427000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00404-021-06118-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,9]]},"references-count":26,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,11]]}},"alternative-id":["6118"],"URL":"https:\/\/doi.org\/10.1007\/s00404-021-06118-3","relation":{},"ISSN":["0932-0067","1432-0711"],"issn-type":[{"value":"0932-0067","type":"print"},{"value":"1432-0711","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,9]]},"assertion":[{"value":"9 September 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 June 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 June 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declared that there was no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}